Eradicating infections and fighting antimicrobial resistance

Morning Meeting Presentation for SB1M

8 December 2021

Today's presenters

SoftOx Solutions AS

CEO Geir Almås

Finance

CFO Kristine Rød

SoftOxRespiratory Tract

CMO-SIS Dr Christopher Burton

Our purpose

MISSION

Helping the world fighting infections

  • Viruses
  • Biofilm Resistance
  • Antimicrobial Resistance

VISION

To become a world-leading developer

of antimicrobial technology

Investment highlights

Proven technology that effectively eradicates bacteria and viruses without creating resistance and answers significant unmet needs

Market approval of winning the Norwegian and Swedish public hospital tenders and free to enter the market through The EU Commission's interpretation of the BPR

Experienced research and development team, with support from Bispebjerg Hospital and University of Copenhagen

85 filed patents worldwide and 57 granted patents addressing formulations, uses, methods and devices

Strong medical technology platform developed over 10+ years with numerous opportunities for future development products

Morning Meeting Presentation for SB1M

Reinforcing nature's own ability to eradicate unwanted microbes

HYPOCHLOROUS

ACETIC

ACID

ACID

SOFTOX TECHNOLOGY

Documented broad

Antimicrobial

antimicrobial effect

stabilizer

Replicating millions of years of evolution

Clinical Results show Superior Effect

Morning Meeting Presentation for SB1M

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

SoftOx Solutions AS published this content on 13 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 13 December 2021 09:45:07 UTC.